HG106

HG106 is an inhibitor of ROS and KRAS used in studies of MAPK / ERK Signaling and Oxidative Stress Response. It is especially relevant in cancer, cell signaling, and metabolism models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and redox signaling, ROS handling, and antioxidant defenses.

By inhibiting ROS and KRAS, HG106 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and redox signaling, ROS handling, and antioxidant defenses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and metabolism models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving ROS and KRAS
• Pathway perturbation studies connected to MAPK / ERK Signaling and Oxidative Stress Response
• Concentration-response inhibition and target-dependence studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, HG106 is appropriate when a defined chemical perturbant is needed to connect ROS and KRAS with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and metabolism models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.